Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

NCT00209638 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: irinotecan
DRUG: S-1

Sponsor

Hokkaido Gastrointestinal Cancer Study Group